ライフサイエンスコーパス: PDE5

1 g" from the channel to the phosphodiesterase PDE5.

2 ligase complex for ubiquitination inhibiting PDE5.

3 erapeutic potential of central inhibition of PDE5.

4 direct competitions with the native binding PDE5.

5 ity of >2000-fold over PDE7, PDE9, PDE2, and PDE5.

6 by a cGMP-dependent phosphodiesterase (PDE), PDE5.

7 iffers from that of sildenafil when bound to PDE5.

8 guanosine monophosphate (cGMP) catabolism by PDE5.

9 f chimerically hybridized or almost inactive PDE5.

10 for cGMP were similar to that of full-length PDE5.

11 ion between PDEgamma(46-87) and the chimeric PDE5/6 catalytic domain confirmed that C-terminal residu

12 Two variable H- and M-loops of PDE5/6cd form a distinct interface that contributes to t

13 Comparison of the two PDE5/6cd structures shows an overlap between the sildena

14 s of a chimaeric PDE5/PDE6 catalytic domain (PDE5/6cd) complexed with sildenafil or 3-isobutyl-1-meth

15 Our results showed that PDE5 abundance increased more than 4-fold in the RVs of

16 AMP-specific PDE3 and PDE4 and cGMP-specific PDE5 activities.

17 The PDE5 activity in systemic and pulmonary vasculature incr

18 resistance pulmonary arteries and increased PDE5 activity in whole lung extracts.

19 This indicates that PDE5 activity limits action potential propagation in neu

20 In HF, PDE5 activity was significantly increased in the systemi

21 We demonstrate that inhibition of PDE5 activity with sildenafil partially rescues cGMP res

22 ization in HF relates, in part, to increased PDE5 activity, supporting a therapeutic role for PDE5 in

23 Phosphodiesterase type 5 (PDE5) acts specifically on cyclic guanosine monophosphat

24 that Gln(817) is a positive determinant for PDE5 affinity for cGMP and several inhibitors; Gln(775),

25 ability to modulate full-length recombinant PDE5 affinity to sildenafil.

26 bition of cGMP-specific phosphodiesterase 5 (PDE5) ameliorates pathological cardiac remodeling and ha

27 similar to that of phosphodiesterase type 5 (PDE5), an enzyme that catalyzes the hydrolysis of second

28 hosphorylation of the cGMP phosphodiesterase PDE5, an enzyme whose activity is increased upon phospho

29 Cells containing PDE5 and alpha-smooth muscle actin occurred throughout t

30 P to GAF-A increases cNPK phosphorylation of PDE5 and improves catalytic site affinity for cGMP or in

31 regulation of PDE6 is more complex than for PDE5 and is dependent on interactions of regions of Pgam

32 se of any known structures of the unliganded PDE5 and its complexes with the inhibitors.

33 PDE5 and nNOS were deficient in 5 of 5 biopsies.

34 esis that class-specific differences between PDE5 and PDE6 account for the biochemical and pharmacolo

35 e to identify functional differences between PDE5 and PDE6 that will accelerate efforts to develop th

36 studies have questioned the role of myocyte PDE5 and protein kinase G (PKG) to this process, proposi

37 nvestigations of the regulatory mechanism of PDE5 and the design of GAF-specific regulators of PDE5 f

38 The conformational variation of both PDE5 and the inhibitors provides structural insight into

39 on the developing pulmonary vasculature and PDE5 are largely unknown.

40 that inhibitors of phosphodiesterase type 5 (PDE5) are increasingly employed in patients with pulmona

41 This work validates the use of PDE5 as a template to identify functional differences be

42 ion, administration of sildenafil to inhibit PDE5 attenuated TAC-induced myocardial oxidative stress,

43 Inhibition of PDE5 by sildenafil suppressed ET-1-induced activation of

44 raining the activity of phosphodiesterase 5 (PDE5) by acting as a substrate adaptor delivering PDE5 t

45 Cocrystal structures of PDE5 catalytic (C) domain with inhibitors reveal a hydro

46 main and gain-of-function mutagenesis of the PDE5 catalytic domain.

47 The results quantify the role of PDE5 catalytic-site residues for cGMP and inhibitors, in

48 The molecular bases for phosphodiesterase 5 (PDE5) catalytic-site affinity for cyclic guanosine monop

49 and protein expression, as well as increased PDE5 cGMP hydrolytic activity.

50 Here, we report the crystal structure of PDE5 complexed with the sole second generation drug avan

51 All PDE5 constructs had similar affinities for 3-isobutyl-1-

52 uired heterologous expression of full-length PDE5 constructs.

53 Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrol

54 ssion in cardiac myocytes and that increased PDE5 contributes to the development of CHF.

55 Phosphodiesterase 5 (PDE5) controls intracellular levels of cGMP through its

56 cells; hence, pharmacological inhibition of PDE5 could affect melanoma risk.

57 We showed previously that PDE5 could be converted from a low-activity (nonactivate

58 vestigated whether sildenafil sensitivity of PDE5 could be modified by cGMP-independent mechanisms.

59 estrated extracellular matrix remodeling via PDE5/cyclic guanosine monophosphate-PKG regulatory pathw

60 these residues are vital for GAF-B-mediated PDE5 dimerization.

61 to block the hyperoxia-mediated increase in PDE5 expression and activity and rescue cGMP responsiven

62 These data suggest that PDE5 expression and activity play a critical role in mod

63 ic FPASMCs with H2O2 is sufficient to induce PDE5 expression and activity, suggesting that reactive o

64 Myocardial PDE5 expression and cellular distribution were determine

65 3 knockout mice caused a greater increase of PDE5 expression and CHF after TAC.

66 These findings suggest that RV PDE5 expression could contribute to the pathogenesis of

67 hesis that oxidative stress causes increased PDE5 expression in cardiac myocytes and that increased P

68 Myocardial oxidative stress increases PDE5 expression in the failing heart.

69 right ventricular (RV) failure, we examined PDE5 expression in the human RV and its impact on myocar

70 d severity-dependent upregulation of myocyte PDE5 expression in the RV and the impact of this upregul

71 nostic target, but noninvasive assessment of PDE5 expression is lacking.

72 PDE5 expression is up-regulated in human hypertrophied a

73 Knock down of PDE5 expression recapitulated the combination effects of

74 from the RV of 20 patients were assayed for PDE5 expression using immunoblot and immunohistochemical

75 PDE5 expression was examined by immunohistochemistry and

76 CHF samples, and the increase of myocardial PDE5 expression was significantly correlated with myocar

77 ted TAC-induced myocardial oxidative stress, PDE5 expression, and CHF.

78 eatment with M40401 attenuated cardiomyocyte PDE5 expression.

79 igh-TG mice received doxycycline to suppress PDE5 expression/activity only in myocytes.

80 gests that reduced phosphodiesterase type 5 (PDE5) expression increases the invasiveness of melanoma

81 ur data demonstrate that high sensitivity of PDE5 for sildenafil can be obtained not only through cGM

82 In human platelet, higher sensitivity of PDE5 for sildenafil inhibition has been detected after b

83 sence of a "super-high" sensitivity state of PDE5 for sildenafil inhibition.

84 the affinity of the nonactivated recombinant PDE5 for sildenafil, revealing much higher sensitivity t

85 first evidence for functional retargeting of PDE5 from one compartment to another, revealing a role f

86 and the design of GAF-specific regulators of PDE5 function.

87 Results yield new insights into PDE5 functions, further define boundaries that provide f

88 es reduced penile PDE activity by decreasing PDE5 gene expression in a HIF-1alpha-dependent manner an

89 ling via ADORA2B activation directly reduces PDE5 gene expression in a hypoxia-inducible factor-1alph

90 th ADA(-/-) and SCD mice by restoring penile PDE5 gene expression to normal levels.

91 th doxycycline-controllable myocyte-specific PDE5 gene expression were generated (medium transgenic [

92 Here we report that phosphodiesterase-5 (PDE5) gene expression and PDE activity is significantly

93 In cGMP-specific PDE5, Gln(775) constrains the orientation of the invaria

94 PDE5 has a well established role in vascular smooth musc

95 PDE5 has two highly homologous regulatory domains, GAF-A

96 ing cyclic-GMP specific phosphodiesterase-5 (PDE5) has attracted much interest in several cardiopulmo

97 cGMP-specific phosphodiesterase (PDE5) has become a target for drug development for the t

98 MCs), and inhibition of phosphodiesterase-5 (PDE5) has been shown to suppress TRPC6 expression in PAS

99 Whereas the closely related PDE5 homodimer undergoes a significant change in its sed

100 the normal heart, phosphodiesterase type 5 (PDE5) hydrolyzes cGMP coupled to nitric oxide- (specific

101 Phosphodiesterase 5 (PDE5) hydrolyzes cyclic guanosine monophosphate (cGMP) l

102 aily doses (DDDs) of MRP inhibitors (NSAIDs, PDE5-i, salicylates, dipyridamole) were collected.

103 PDE5 (important in regulating vascular smooth muscle con

104 Inhibition of phosphodiesterase 5 (PDE5) improves cardiac function in mouse models of DBMD.

105 explained by a significant downregulation of PDE5 in muscle.

106 12 and [(18)F]-17 showed specific binding to PDE5 in myocardium of transgenic mice; however [(18)F]-1

107 ing heart, suggesting a significant role for PDE5 in the development of congestive heart failure (CHF

108 also through cGMP-independent modulation of PDE5 in the nonactivated state, possibly through protein

109 Our aim was to establish the distribution of PDE5 in the pulmonary vasculature and effects of PDE5 in

110 hosphate-selective phosphodiesterase type 5 (PDE5) influences maladaptive remodeling in hearts subjec

111 Rather, PDE5 inhibition decreased resting levels of ATP, phospho

112 PDE5 inhibition did not alter atrial natriuretic peptide

113 Because PDE5 inhibition elevates cGMP and protects from doxorubi

114 ses in HF rendering hemodynamic responses to PDE5 inhibition identical to those from BNP infusion.

115 i and colleagues reveal that the efficacy of PDE5 inhibition in female mice requires estrogen.

116 Importantly, PKG was similarly activated by PDE5 inhibition in myocardium from both genotypes, but P

117 Chronic PDE5 inhibition in the short-to-intermediate duration st

118 failure, and direct myocardial responses to PDE5 inhibition may modulate the indirect responses medi

119 in the pulmonary vasculature and effects of PDE5 inhibition on pulmonary artery smooth muscle cells

120 In functional studies, PDE5 inhibition produced little change in developed forc

121 In several mouse tumor models, PDE5 inhibition reverses tumor-induced immunosuppressive

122 tcome studies are currently lacking, chronic PDE5 inhibition should be considered in carefully select

123 cytes than in controls and was unaffected by PDE5 inhibition.

124 activity, supporting a therapeutic role for PDE5 inhibition.

125 Phosphodiesterase type 5 (PDE5) inhibition has been shown to exert profound benefi

126 evolving role for phosphodiesterase type 5 (PDE5) inhibition in patients with pulmonary hypertension

127 s to test whether acute phosphodiesterase 5 (PDE5) inhibition via sildenafil (SIL) mimics and/or pote

128 GAF-B contributes to dimerization of PDE5, inhibition of cGMP binding to GAF-A, and sequestra

129 ly overcome by combing HBOC treatment with a PDE5 inhibitor (sildenafil).

130 ent animal and human data support the use of PDE5 inhibitor and the generation of early erections aft

131 imal and human studies imply that the use of PDE5 inhibitor and the generation of erections early aft

132 Ever use of a PDE5 inhibitor and time-updated cumulative number of PDE

133 All men initiating a PDE5 inhibitor and with no prior cancer diagnosis were i

134 ion recapitulated the combination effects of PDE5 inhibitor drugs with chemotherapy drugs.

135 nclusion, the safety and efficacy profile of PDE5 inhibitor PF-00489791 supports further investigatio

136 145,104 men with >/=1 PDE5 inhibitor prescription, and 560,933 unexposed match

137 ibitor and time-updated cumulative number of PDE5 inhibitor prescriptions were investigated as exposu

138 f tauopathies or Huntington's disease with a PDE5 inhibitor reduced the levels of the mutant huntingt

139 mising results in males, the efficacy of the PDE5 inhibitor sildenafil in female cardiac pathologies

140 d in vivo, but it has been proposed that the PDE5 inhibitor sildenafil is prothrombotic.

141 n follow-on experiments the influence of the PDE5 inhibitor tadalafil on the development of doxorubic

142 continued investigation of combined HBOC and PDE5 inhibitor treatment in circumstances in which HBOC

143 t solar keratosis was associated with future PDE5 inhibitor use (odds ratio = 1.28, 95% CI 1.23-1.34,

144 ence of a small positive association between PDE5 inhibitor use and melanoma risk (HR = 1.14, 95% CI

145 We therefore aimed to investigate whether PDE5 inhibitor use is associated with an increased risk

146 PDE5 inhibitor use was also associated with an increased

147 gher sun exposure were more likely to become PDE5 inhibitor users.

148 The most potent PDE5 inhibitor was sildenafil.

149 -polymerized bovine hemoglobin (HBOC) with a PDE5 inhibitor would counter the negative hemodynamic co

150 erized bovine hemoglobin (HBOC), sildenafil (PDE5 inhibitor), and lactated Ringer's solution (control

151 and is additive with prostacyclin analogues, PDE5 inhibitor, and NO.

152 effects of tadalafil (Cialis), a long acting PDE5 inhibitor, on brain cGMP levels, neurogenesis, angi

153 the novel, highly specific, and long-acting PDE5 inhibitor, PF-00489791, was assessed in a multinati

154 ddition, treatment of mdx(5cv) mice with the PDE5 inhibitor, sildenafil, which was one of the six dru

155 This study compared adding sildenafil, a PDE5 inhibitor, to conventional treatment with the curre

156 The corona phase binds selectively to a PDE5 inhibitor, Vardenafil, as well as its molecular var

157 aimed to assess the effects of tadalafil--a PDE5 inhibitor--on exercise capacity and quality of life

158 ter sun exposure among patients exposed to a PDE5 inhibitor.

159 postinil, inorganic nitrate (NO donor), or a PDE5 inhibitor.

160 on of nNOS effects by a phosphodiesterase 5 (PDE5) inhibitor (sildenafil) improves skeletal and cardi

161 denafil citrate, a phosphodiesterase type 5 (PDE5) inhibitor and potent vasodilator.

162 Sildenafil, a phosphodiesterase-5 (PDE5) inhibitor causing accumulation of cGMP, is frequen

163 udies indicate that the phosphodiesterase 5 (PDE5) inhibitor sildenafil is protective against hypertr

164 Surprisingly, the phosphodiesterase 5 (PDE5) inhibitor sildenafil was found to possess submicro

165 nafil, a type 5 phosphodiesterase isoenzyme (PDE5) inhibitor with a short half-life, increases brain

166 fil citrate (Viagra), a phosphodiesterase 5 (PDE5) inhibitor, can be used to ameliorate the age-relat

167 dition of sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, in the drinking water had a small effec

168 , NY), a selective phosphodiesterase type-5 (PDE5) inhibitor, is widely used to treat impotence by im

169 t of Sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, on nestin lineage neural stem cells and

170 a highly-specific type 5 phosphodiesterase (PDE5) inhibitor, on platelet-mediated cyclic coronary fl

171 y sildenafil, a popular phosphodiesterase 5 (PDE5) inhibitor.

172 To determine whether the PDE5-inhibitor sildenafil benefits human dystrophinopath

173 PDE5 inhibitors (eg, sildenafil) are licensed for PH, bu

174 an increased risk of melanoma in men taking PDE5 inhibitors (OR, 1.21 [95% CI, 1.08-1.36]).

175 eclinical and experimental studies show that PDE5 inhibitors (PDE5is) exert protective effects in DN

176 e previously reported potent quinoline-based PDE5 inhibitors (PDE5Is) for the treatment of Alzheimer'

177 PDE5 inhibitors (sildenafil, tadalafil, vardenafil, etc.

178 Further, the combination of PDE5 inhibitors and agents that increase cGMP or cAMP al

179 Combination of PDE5 inhibitors and alpha1-adrenergic blockers may have

180 Combination therapy using PDE5 inhibitors and alpha1-adrenergic blockers resulted

181 Treatment with PDE5 inhibitors and chemotherapy drugs promoted autophag

182 Given that side effects of PDE5 inhibitors are widely known and do not preclude the

183 dings demonstrate a potentially novel use of PDE5 inhibitors as adjuncts to tumor-specific immune the

184 We report the use of PDE5 inhibitors as modulators of the antitumor immune re

185 The PDE5 inhibitors augment the antithrombotic effects of ni

186 Our results were not consistent with PDE5 inhibitors being causally associated with melanoma

187 It is recognized that PDE5 inhibitors can have cardioprotective effects in oth

188 PDE5 inhibitors enhanced and prolonged the induction of

189 research, highlight the potential utility of PDE5 inhibitors for ameliorating emotion recognition def

190 This article focuses on the use of PDE5 inhibitors for BPH/LUTS treatment and highlights th

191 importance of sex differences in the use of PDE5 inhibitors for treating heart disease and the criti

192 Men taking PDE5 inhibitors had a higher educational level and annua

193 Specifically, post-operative use of PDE5 inhibitors has a strong anti-cancer effect.

194 Recently, PDE5 inhibitors have been found to regulate smooth muscl

195 PDE5 inhibitors have the potential to be an adjuvant dru

196 especially after the therapeutic success of PDE5 inhibitors in the treatment of erectile dysfunction

197 e safety, efficacy and cost-effectiveness of PDE5 inhibitors in the treatment of LUTS secondary to BP

198 tumor cells expressing mutant active K-RAS, PDE5 inhibitors interacted in a greater than additive fa

199 onal status, at clinically achievable doses, PDE5 inhibitors interacted in a greater than additive fa

200 Here we show that post-diagnostic use of PDE5 inhibitors is associated with a decreased risk of C

201 As well, chronic administration of PDE5 inhibitors may also help maintain the smooth muscle

202 Overall, the data suggest that PDE5 inhibitors may be a useful treatment for the cardio

203 tudies have provided promising evidence that PDE5 inhibitors may be an effective and well tolerated t

204 it appears from recent clinical studies that PDE5 inhibitors may increase the risk of malignant melan

205 The present study tested PDE5 inhibitors on the cGMP-mediated modulation of K(+)

206 g critical insights into the side effects of PDE5 inhibitors on vision.

207 ata demonstrates that oral administration of PDE5 inhibitors selectively increases BTB permeability a

208 Number of filled prescriptions for the PDE5 inhibitors sildenafil and vardenafil or tadalafil.

209 nic treatment of pulmonary hypertension with PDE5 inhibitors such as sildenafil.

210 PDE5 inhibitors such as Viagra block the activity of suP

211 otide field that culminated in the advent of PDE5 inhibitors that treat erectile dysfunction, such as

212 larities with PDE5, we utilized radiolabeled PDE5 inhibitors to probe the catalytic sites of PDE6.

213 e has been increasing interest in the use of PDE5 inhibitors to treat BPH/LUTS.

214 ed to explore whether post-diagnostic use of PDE5 inhibitors was associated with a better prognosis a

215 In a Swedish cohort of men, the use of PDE5 inhibitors was associated with a modest but statist

216 PDE5 inhibitors were significantly associated with melan

217 device therapy, dietary supplementation and PDE5 inhibitors which is described in detail.

218 our data demonstrate that the combination of PDE5 inhibitors with standard of care chemotherapy agent

219 , 435 men (11%) had filled prescriptions for PDE5 inhibitors, as did 1713 men of 20,325 controls (8%)

220 ts of long-term treatments with low doses of PDE5 inhibitors.

221 a novel series of aminopyridopyrazinones as PDE5 inhibitors.

222 hypertrophic and cardioprotective effects of PDE5 inhibitors.

223 Phosphodiesterase-5 (PDE5) inhibitors (sildenafil, tadalafil, and vardenafil)

224 Phosphodiesterase-5 (PDE5) inhibitors are suggested to have anti-tumor effect

225 Phosphodiesterase-5 (PDE5) inhibitors improve exercise capacity and quality o

226 Phosphodiesterase-5 (PDE5) inhibitors increase intracellular concentrations o

227 her clinically relevant phosphodiesterase 5 (PDE5) inhibitors interacted with clinically relevant che

228 Phosphodiesterase 5 (PDE5) inhibitors limit myocardial injury caused by stres

229 Phosphodiesterase-5 (PDE5) inhibitors promote nitric oxide activity and enhan

230 dysfunction drugs, phosphodiesterase type 5 (PDE5) inhibitors, is part of a pathway implicated in the

231 nduction are blocked by phosphodiesterase 5 (PDE5) inhibitors.

232 PDE5 is upregulated in hypertrophied and failing hearts

233 Phosphodiesterase 5A1 (PDE5) is a key target for treating cardiovascular diseas

234 The activity of phosphodiesterase-5 (PDE5) is specific for cGMP and is regulated by cGMP bind

235 Phosphodiesterase-5 (PDE5) is the target for sildenafil, vardenafil, and tada

236 hydrolyzing enzyme phosphodiesterase type 5 (PDE5) might exert renoprotective effects in DN.

237 naling also can promote steroidogenesis, and PDE5 modulates this process.

238 al consequence and the therapeutic impact of PDE5 modulation in heart disease.

239 ng the up-regulation of TRPC6 expression and PDE5 modulation of TRPC6 expression in PASMCs remain lar

240 eased intracellular cGMP response, increased PDE5 mRNA and protein expression, as well as increased P

241 However, the role of PDE5 outside of the vasculature has received little atte

242 T-1032, a compound with high specificity for PDE5 over PDE6, had a similar action.

243 Mice with cardiac myocyte inducible PDE5 overexpression (P5(+)) were crossed to those lackin

244 transgenic mice with cardiomyocyte-specific PDE5 overexpression at 30 min postinjection.

245 nitric oxide/cyclic guanosine monophosphate/PDE5 pathway in the treatment of BPH/LUTS deserve furthe

246 exert vasodilation through inhibition of the PDE5 pathway independent of ERK signaling.

247 GS19 (GAIP), calbindin, GC1alpha2, GC1beta2, PDE5, PDE2A, amiloride-sensitive sodium channel ACCN4, a

248 Here, crystal structures of a chimaeric PDE5/PDE6 catalytic domain (PDE5/6cd) complexed with sil

249 d loss-of-function mutagenesis of a chimeric PDE5/PDE6 catalytic domain and gain-of-function mutagene

250 hydrolysis is increased by activation of the PDE5 phosphodiesterase.

251 Thus, PDE5 plays an important role in the regulation of neuroh

252 te (cGMP) specific phosphodiesterase type 5 (PDE5) plays an important role in various pathologies inc

253 This and selective inhibition of PDE5 protected the heart against pressure overload-induc

254 to attenuate oxidative stress, the increased PDE5 protein and activity caused by TAC was blunted, and

255 Myocardial PDE5 protein content and activity also increased in mice

256 with 100% O2 for 24 hours leads to increased PDE5 protein expression in the resistance pulmonary arte

257 of PDE6 residues into the background of the PDE5 protein sequence often led to loss of catalytic act

258 Compared with donor human hearts, myocardial PDE5 protein was increased approximately equal 4.5-fold

259 PDE5(Q817A) and PDE5(Q775A) were generated to test the hypotheses that G

260 For PDE5(Q775A), K(m) for cGMP was weakened approximately 20

261 affinity were not significantly affected in PDE5(Q775A).

262 PDE5(Q817A) and PDE5(Q775A) were generated to test the h

263 For PDE5(Q817A), K(m) for cGMP or cAMP was weakened 60- or 2

264 For PDE5(Q817A), vardenafil, sildenafil, and IBMX inhibitory

265 To probe potential PDE5 R domain effects on catalytic site affinity for cer

266 This is the first evidence that PDE5 R domain, and GAF-B in particular, influences affin

267 a strongly support a primary role of myocyte PDE5 regulation to myocardial pathobiology and PDE5 targ

268 The features of the PDE5 regulatory domain revealed here provide an initial

269 PDE5 represents an important therapeutic and/or prognost

270 Replacing human PDE5 residues in the M-loop region of the binding site f

271 viously reported NMR structure of cGMP-bound PDE5 revealed dramatic conformational differences and su

272 A PDE5 selective inhibitor that has an IC(50) of 230 nm fo

273 he M-loop region of the binding site for the PDE5-selective inhibitor tadalafil (Cialis(R)) with the

274 te efforts to develop the next generation of PDE5-selective inhibitors with fewer adverse side effect

275 nafil (Levitra), inhibitors of cGMP-specific PDE5, selectively increased tumor capillary permeability

276 nt results of point mutations of full-length PDE5 showed that maximum catalysis was decreased 2650-fo

277 port that the phosphodiesterase 5 inhibitor (PDE5) sildenafil (Viagra), a molecule that enhances phos

278 wever [(18)F]-17 showed significantly higher PDE5-specific inhibitable binding than [(11)C]-12.

279 ves labeled with carbon-11 or fluorine-18 as PDE5-specific PET tracers.

280 In biodistribution studies, highest PDE5-specific retention was observed for [(11)C]-12 and

281 od-brain barrier but brain retention was not PDE5-specific.

282 rises in such diseases, we hypothesized that PDE5 substrate selectivity is retargeted to blunt NP-der

283 smooth muscle, where specific inhibitors of PDE5 such as sildenafil correct erectile dysfunction by

284 ition of cGMP-selective phosphodiesterase 5 (PDE5) suppressed maladaptive cardiac hypertrophy, inhibi

285 /NFATc4 signaling pathway, and inhibition of PDE5 suppresses calcineurin/NFATc4- mediated TRPC6 expre

286 The channel/PDE5 tandem encodes cGMP turnover rates rather than conc

287 E5 regulation to myocardial pathobiology and PDE5 targeting therapy in vivo and reveal a novel mechan

288 has higher affinity to phosphodiesterase-5 (PDE5) than sildenafil and lower administered dosage for

289 In PDE2 and PDE5, the GAF domains mediate cGMP stimulation; however,

290 e, it maintains a tonic inhibitory effect on PDE5, thereby delaying the degradation of cGMP.

291 by acting as a substrate adaptor delivering PDE5 to the Cullin-3 E3 Ring ubiquitin ligase complex fo

292 s functional retargeting was associated with PDE5 translocation from sarcomeres to a dispersed distri

293 In dilated cardiomyopathy, PDE5 upregulation was more moderate and varied with the

294 Class-specific differences in PDE5 versus cone PDE6 that contribute to the accelerated

295 re not affected, whereas the contribution of PDE5 was increased.

296 Histological examination demonstrated that PDE5 was mainly expressed in vascular smooth muscle in n

297 ctural and pharmacological similarities with PDE5, we utilized radiolabeled PDE5 inhibitors to probe

298 Three molecular forms of PDE5 were identified and protein expression was greater

299 Muscle nNOS and PDE5 were tested with Western blotting in 5 patients.

300 Furthermore, data suggest that nonactivated PDE5 with "super-high" affinities for sildenafil inhibit

301 mutant proteins were unchanged compared with PDE5(WT).